TR200202033T2 - Epilepsi Tedavisi İçin Terkipler ve Yöntemler - Google Patents

Epilepsi Tedavisi İçin Terkipler ve Yöntemler

Info

Publication number
TR200202033T2
TR200202033T2 TR2002/02033T TR200202033T TR200202033T2 TR 200202033 T2 TR200202033 T2 TR 200202033T2 TR 2002/02033 T TR2002/02033 T TR 2002/02033T TR 200202033 T TR200202033 T TR 200202033T TR 200202033 T2 TR200202033 T2 TR 200202033T2
Authority
TR
Turkey
Prior art keywords
preparations
methods
epilepsy treatment
mammal
epilepsy
Prior art date
Application number
TR2002/02033T
Other languages
English (en)
Inventor
B. Margolin Solomon
Original Assignee
Cymar Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymar Inc. filed Critical Cymar Inc.
Publication of TR200202033T2 publication Critical patent/TR200202033T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Bir epileptik durumu olan bir memelinin tedavisi için;söz konusu memeliye etkili miktarda bir N-fenil ikameli 2-piridon bilesimi ve/veya farmasötik olarak kabul edilebilir tuzlarini içeren bir farmasötik terkibin verilmesini içeren bir yöntem
TR2002/02033T 2000-02-21 2000-02-21 Epilepsi Tedavisi İçin Terkipler ve Yöntemler TR200202033T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/005221 WO2001062253A1 (en) 2000-02-21 2000-02-21 Compositions and methods for treatment of epilepsy

Publications (1)

Publication Number Publication Date
TR200202033T2 true TR200202033T2 (tr) 2003-01-21

Family

ID=21741103

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/02033T TR200202033T2 (tr) 2000-02-21 2000-02-21 Epilepsi Tedavisi İçin Terkipler ve Yöntemler

Country Status (11)

Country Link
EP (1) EP1261338B1 (tr)
JP (1) JP2003523391A (tr)
KR (1) KR20020081334A (tr)
AU (2) AU2000237125B2 (tr)
CA (1) CA2400491A1 (tr)
DE (1) DE60028831D1 (tr)
IL (1) IL151403A0 (tr)
MX (1) MXPA02008132A (tr)
NO (1) NO20023944L (tr)
TR (1) TR200202033T2 (tr)
WO (1) WO2001062253A1 (tr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7825133B2 (en) 2003-11-14 2010-11-02 Shanghai Genomics, Inc. Derivatives of pyridone and the use of them
MX2007014114A (es) 2005-05-10 2008-03-14 Intermune Inc Derivados de piridona para modular el sistema de proteina cinasa activada por estres.
ES2358297T3 (es) * 2006-06-05 2011-05-09 Novartis Ag Compuestos orgánicos.
JP5627574B2 (ja) 2008-06-03 2014-11-19 インターミューン， インコーポレイテッド 炎症性および線維性疾患を治療するための化合物および方法
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
JP6525437B2 (ja) 2014-04-02 2019-06-05 インターミューン， インコーポレイテッド 抗線維性ピリジノン

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2947755A (en) * 1959-02-05 1960-08-02 Wallace & Tiernan Inc Substituted 1-m-aminophenyl-2-pyridones
US5962478A (en) * 1995-09-19 1999-10-05 Margolin; Solomon B. Inhibition of tumor necrosis factor α
ATE332135T1 (de) * 2000-01-24 2006-07-15 Solomon B Margolin Behandlung von brustkarzinomen, astrozytomen, melanomen und verwandten tumoren

Also Published As

Publication number Publication date
WO2001062253A1 (en) 2001-08-30
MXPA02008132A (es) 2004-11-12
EP1261338A4 (en) 2004-05-06
KR20020081334A (ko) 2002-10-26
AU2000237125B2 (en) 2005-12-08
IL151403A0 (en) 2003-04-10
CA2400491A1 (en) 2001-08-30
NO20023944D0 (no) 2002-08-20
DE60028831D1 (de) 2006-07-27
AU3712500A (en) 2001-09-03
JP2003523391A (ja) 2003-08-05
NO20023944L (no) 2002-09-23
EP1261338A1 (en) 2002-12-04
EP1261338B1 (en) 2006-06-14

Similar Documents

Publication Publication Date Title
DK1169060T3 (da) Natriumkanalblokkerpræparater og anvendelse deraf
EG25822A (en) Quinolinyl-pyrrolopyrazoles
CY1109242T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
PL333920A1 (en) 3-pyridyl enantiomers and their application as pain-relieving agents
EA200101089A1 (ru) Новый способ лечения
BR9814923A (pt) Método para tratamento de doença de alzheimer
DK0699439T3 (da) Behandling af sygdomme forårsaget af talgkirtellidelser med acyl-CoA-cholesterolacyltransferaseinhibitorer
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
TR200202033T2 (tr) Epilepsi Tedavisi İçin Terkipler ve Yöntemler
WO2001080813A3 (en) Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy
DK0986393T3 (da) Anvendelse af et nitroxid eller et prodrug heraf ved profylaktisk og terapeutisk behandling af cancer
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
TR200103561T2 (tr) Rodanin türevleri ve amiloidlerin önlenmesi ve görüntülenmesinde kullanımları
AU4937499A (en) Use of succinic acid or salts thereof and method of treating insulin resistance
TR199801133T2 (tr) Tip II diyabetin tedavisi veya önlenmesi için nitrik oksit (NO) sentaz inhibitörü
US6541495B1 (en) Carboxylic acid derivatives as inhibitors of hyperproliferation diseases
NZ521518A (en) Compositions and methods for treatment of epilepsy
MX9605153A (es) Agentes farmaceuticos para el tratamiento de enfermedades inflamatorias cronicas y agudas.
MX9701529A (es) Uso de (e)-1-[4'-(2-alquilaminoetoxi)fenil]-1-(3'-hidroxifenil)-2-f enilbut-1-enos para inhibir trastornos patologicos.